ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2146

Clinical Characterization of Itch in Dermatomyositis and the Role of Increased Skin Interleukin-31

Hee Joo Kim1,2,3, Diletta Bonciani1,2,4, Sandra M. Pena2, Janice Tiao2, Padma Sahu1,2, Muhammad M. Bashir1,2 and Victoria P. Werth1,2, 1Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, 2Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, The Republic of, 4Department of Surgery and Translational Medicine, Section of Dermatology, University of Florence, Florence, Italy

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Dermatomyositis and interleukins (IL)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Interleukin-31 (IL-31) has been implicated in pruritus associated with various itchy skin diseases, including atopic dermatitis and cutaneous T cell lymphoma. While pruritus is a prominent feature in dermatomyositis (DM), there are few studies to evaluate clinical characteristics and pathogenesis of itch in DM. We examined the prevalence and severity of pruritus in patients with DM, and investigated the presence of IL-31 and IL-31 receptor in skin tissue to explain the pathomechanism of itch in DM patients.

Methods: Pruritus and disease activity of DM were evaluated by a visual analog scale (VAS) and the Cutaneous Disease and Activity Severity Index (CDASI), respectively. Gene expression of IL-31 and IL-31 receptor alpha (IL-31RA) in lesional DM skin was evaluated by qRT-PCR, and was compared with that of non-lesional DM skin, and skin tissue of cutaneous lupus erythematosus (CLE) patients and healthy controls (HC). Immunohistochemical analysis assessed IL-31 expression in skin tissue. The Spearman rank test was used to evaluate the relationship between itch intensity and disease activity, as well as itch intensity and lesional gene expression of IL-31 and IL-31RA. The Kruskal-Wallis test with Dunn’s post hoc test was used to compare the difference of IL-31 and IL-31RA mRNA expression, and immunohistochemical analysis of skin IL-31 expression in DM and HC.

Results: About half of 164 patients with DM (25 male, 139 female; 61 classic DM and 103 clinically amyopathic DM; mean age ± SD 52.5 ± 14 years) had moderate to severe itch (28.66% moderate, 20.73% severe itch). Pruritus in DM was positively correlated with disease activity, with a correlation coefficient of 0.337 between VAS itch score and CDASI activity score (p<0.01). Skin IL-31 and IL-31RA gene expression was significantly up-regulated in DM compared to HC and CLE (p<0.05). IL-31 mRNA expression was positively correlated with VAS itch score (r= 0.7619, p=0.03). Immunoreactivity for IL-31 was also stronger in lesional skin of DM (p=0.0001).

Conclusion: In conclusion, we confirmed that itch is a prevalent symptom in many patients with DM involving the skin, and that skin IL-31 is significantly higher in DM than CLE and HC. This is the first study to suggest IL-31’s crucial role in the skin for pruritus in DM.


Disclosure: H. J. Kim, None; D. Bonciani, None; S. M. Pena, None; J. Tiao, None; P. Sahu, None; M. M. Bashir, None; V. P. Werth, None.

To cite this abstract in AMA style:

Kim HJ, Bonciani D, Pena SM, Tiao J, Sahu P, Bashir MM, Werth VP. Clinical Characterization of Itch in Dermatomyositis and the Role of Increased Skin Interleukin-31 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/clinical-characterization-of-itch-in-dermatomyositis-and-the-role-of-increased-skin-interleukin-31/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characterization-of-itch-in-dermatomyositis-and-the-role-of-increased-skin-interleukin-31/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology